Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252343 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
NCT00252343 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 360 participants.
The verdict
NCT00252343, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
Study Summary
To evaluate the efficacy of a fixed dose of SR58611A (350mg q12) compared to placebo in patients with GeneralizedAnxiety Disorder (GAD) using escitalopram (10 mg qd) as positive control. To evaluate the tolerability and safety of SR58611A in patients with GAD.
Interventions
- DRUG SR58611A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252343
The ClinicalTrials.gov registry entry for NCT00252343 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SR58611A is the first listed.
NCT00252343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00252343 about?
NCT00252343 is a clinical study titled "Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder". To evaluate the efficacy of a fixed dose of SR58611A (350mg q12) compared to placebo in patients with GeneralizedAnxiety Disorder (GAD) using escitalopram (10 mg qd) as positive control. To evaluate the tolerability and safety of SR58611A in patients with GAD.
What is the current status of trial NCT00252343?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2005-09. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00252343?
The interventions under investigation include: SR58611A (DRUG).
Who is sponsoring clinical trial NCT00252343?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.